As noted in President Lott's article, member involvement and leadership development are among the core values of CPNP. As result, one of the Board's three overarching priorities this year involves nurturing the culture of volunteerism to help grow future leaders and mold our specialty over the coming decades.

In the hustle and bustle of our work and personal lives, it is often challenging to even think about volunteering for your association. CPNP's newest video features several members talking about the tremendous value of volunteering for CPNP—benefits and rewards that can far outweigh the challenges of including these activities in your life.

Feeding off our existing volunteer profile, CPNP has also created a quick reference point for existing volunteer opportunities. These opportunities are varied ranging from one-time, brief tasks to one-year appointments to standing committees. As opportunities become available, CPNP will post a complete “job description” along with projected time commitment and duration in the opportunities center. These opportunities can be accessed under the My CPNP pages of the website, will be listed in the weekly update distributed on Mondays and will be communicated via a weekly email on Wednesdays (if new opportunities are posted). We expect that this new feature will provide CPNP committees, staff and leadership with an excellent way to involve members in important issues but in more varying ways. Members should be able to locate volunteer opportunities that work with their schedules and interests. Already 85 members have responded to the new opportunities section!

We look forward to working with you on one or more of many activities that CPNP engages in to advance CPNP and the profession!

Schizophrenia is a chronic, debilitating disorder in which successful long-term management represents a considerable clinical challenge. However, recent advances in the field are beginning to show promise toward enabling clinicians to render effective, personalized care. This Negative Symptoms in Schizophrenia enduring will examine diagnostic tools for effective symptom assessment in schizophrenia and evolving theories on the pathogenesis of schizophrenia. The limitations of current antipsychotics will also be discussed, as well as the emergence of novel therapeutics with unique receptor binding profiles with the potential to improve patient outcomes.

This complimentary, knowledge-based course consists of four modules (each valued at .5 contact hours of ACPE credit) authored by psychiatric pharmacists on the following topics:

Module 1: Symptom Classification in Schizophrenia (Deanna Kelly, PharmD, BCPP)

Module 2: Pathophysiology of Schizophrenia: Neurotransmitters, Receptors and Genetics(Roger W. Sommi, PharmD, FCCP, BCPP)

Module 3: Management of Schizophrenia (Steven Stoner, PharmD, BCPP and Beth Winans, PharmD, BCPP)

Module 4: The Future of Schizophrenia Management (Deanna Kelly, PharmD, BCPP)

There is no fee for the activity and participants must successfully complete an exam and evaluation at the end of each module in order to receive 2.0 contact hour (0.20 CEUs) of continuing pharmacy education credit. Take advantage of this great opportunity now.

CPNP is once again playing a role in the ASHP Midyear Clinic Meeting taking place December 2–6, 2012 in Las Vegas at the Mandalay Bay Hotel.

Sunday, December 2, 2:30–4:00 pm

Attend the Psychopharmacy/Neurology Networking Session facilitated by Cherry Jackson, PharmD, BCPP, FASHP. If you have topics for discussion, you may contact Cherry Jackson.

Monday, December 3, 2:00–3:30 pm

Attend "Expecting the Unexpected: Treatment of Opiate Dependence in Pregnancy" an advanced level program co-sponsored by CPNP. This same course will be repurposed for recertification credit at the 2013 CPNP Annual Meeting. This session is moderated by Sarah Melton, PharmD, BCPP, CGP and instructed by Susan Sonne, PharmD, BCPP. Learning objectives include:

  1. Evaluate evidence-based literature regarding treatment of opioid dependency during pregnancy with buprenorphine or methadone.

  2. Contrast the benefits and disadvantages associated with use of buprenorphine or methadone in pregnant women.

  3. Discuss the management of intrapartum and postpartum pain in opioid dependent patients.

  4. Examine the incidence and treatment of neonatal abstinence syndrome associated with buprenorphine and methadone use in pregnancy.

  5. Develop best practices in treating women with opiate dependence based on evaluation of the primary literature.

  6. Provide medication education to patients and families of pregnant women with opiate dependence.

Tuesday, December 4, 1:00–4:00 pm

You can visit the CPNP residency showcase booth (#6004) where CPNP members will be promoting psychiatric pharmacy as a residency and career choice. If you are attending and want to volunteer to help staff the booth, contact Amber Riesselman.

Congratulations!

Jessica Cather, PharmD, BCPP, BCPS, had a baby girl on 10/3/12.

Charles Caley, PharmD, BCPP, is now Clinical Professor at the University of Connecticut.

Barbara Wells, PharmD, FCCP, BCPP, was named the 2012 Paul F. Parker Medalist by the American College of Clinical Pharmacy. Read the press release.

C. Lindsay DeVane, PharmD, BCPP, FCCP, will be new editor in chief of Pharmacotherapy!